Semanteon Capital Management LP Takes Position in Envista Holdings Co. (NYSE:NVST)

Semanteon Capital Management LP purchased a new stake in shares of Envista Holdings Co. (NYSE:NVST) in the fourth quarter, HoldingsChannel.com reports. The fund purchased 36,439 shares of the company’s stock, valued at approximately $877,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Headinvest LLC acquired a new stake in shares of Envista during the 3rd quarter valued at approximately $28,000. Fifth Third Bancorp increased its stake in shares of Envista by 98.1% during the 4th quarter. Fifth Third Bancorp now owns 1,254 shares of the company’s stock worth $30,000 after purchasing an additional 621 shares in the last quarter. Itau Unibanco Holding S.A. purchased a new position in shares of Envista during the 3rd quarter worth approximately $47,000. Signaturefd LLC increased its stake in shares of Envista by 1,297.9% during the 4th quarter. Signaturefd LLC now owns 2,614 shares of the company’s stock worth $63,000 after purchasing an additional 2,427 shares in the last quarter. Finally, Covestor Ltd increased its stake in shares of Envista by 33.9% during the 3rd quarter. Covestor Ltd now owns 2,462 shares of the company’s stock worth $69,000 after purchasing an additional 624 shares in the last quarter.

Envista Stock Up 1.8 %

Shares of NYSE:NVST traded up $0.37 during midday trading on Friday, hitting $20.39. 1,816,938 shares of the company’s stock traded hands, compared to its average volume of 2,303,126. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.90 and a current ratio of 2.23. The company has a market cap of $3.50 billion, a PE ratio of -33.43, a P/E/G ratio of 3.79 and a beta of 1.35. The firm’s fifty day moving average price is $20.95 and its two-hundred day moving average price is $22.72. Envista Holdings Co. has a twelve month low of $18.95 and a twelve month high of $38.68.

Envista (NYSE:NVST) last issued its quarterly earnings data on Wednesday, February 7th. The company reported $0.29 EPS for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.04). Envista had a positive return on equity of 6.31% and a negative net margin of 3.90%. The firm had revenue of $645.60 million during the quarter, compared to analyst estimates of $638.37 million. During the same quarter in the prior year, the firm earned $0.52 EPS. The business’s quarterly revenue was down 2.3% compared to the same quarter last year. On average, equities research analysts anticipate that Envista Holdings Co. will post 1.43 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on NVST shares. William Blair cut shares of Envista from an “outperform” rating to a “market perform” rating in a research note on Thursday, February 8th. TheStreet cut shares of Envista from a “c” rating to a “d+” rating in a research note on Wednesday, February 7th. Morgan Stanley cut shares of Envista from an “overweight” rating to an “equal weight” rating and dropped their price objective for the stock from $33.00 to $21.00 in a research note on Friday. SVB Leerink began coverage on shares of Envista in a research note on Monday, February 26th. They issued an “underperform” rating and a $19.00 target price for the company. Finally, Leerink Partnrs reaffirmed an “underperform” rating on shares of Envista in a research note on Monday, February 26th. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $27.90.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.